Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes

Correction: BMC Ophthalmol 23, 279 (2023)

https://doi.org/10.1186/s12886–023-03012-1

After publication of the original article [1], the author group noticed a calculation error that has affected Tables 3 and 5 as well as the second paragraph of the Results section in page 4.

Table 3.

Baseline lipid parameters in patients on alirocumab with ≥ 2 consecutive LDL-C values < 25 mg/dL and propensity score-matched patients on placebo

	All ( N  = 8610)	Alirocumab ( N  = 4305)	Placebo ( N  = 4305)
LDL-C, mmol/L	2.1 ± 0.6	2.1 ± 0.6	2.16 ± 0.
Non-HDL-C, mmol/L	2.9 ± 0.7	2.9 ± 0.7	2.9 ± 0.7
Total cholesterol, mmol/L	4.0 ± 0.8	4.0 ± 0.8	4.0 ± 0.8
HDL-C, mmol/L	1.1 ± 0.3	1.1 ± 0.3	1.1 ± 0.3
Fasting triglycerides, mmol/L	1.8 ± 1.0	1.8 ± 1.0	1.8 ± 1.1
Lipoprotein(a), mg/dL	28.6 ± 33.1	28.7 ± 33.3	28.7 ± 33.2
Apolipoprotein B, mg/dL	77.6 ± 17.3	78.1 ± 17.5	77.9 ± 17.4
Apolipoprotein A1, mg/dL	131.6 ± 23.0	131.2 ± 22.5	131.4 ± 22.7
Apolipoprotein B/Apolipoprotein A1 ratioa	0.61 ± 0.2	0.61 ± 0.2	0.61 ± 0.2
Total cholesterol/HDL-C ratioa	3.8 ± 1.0	3.8 ± 1.0	3.8 ± 1.0

Data are presented as mean ± SD

HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Q quartile, SD standard deviation

^a Ratios were only calculated if the 2 samples were collected at the same visit

Table 5.

Baseline lipid parameters in patients on alirocumab with ≥ 2 consecutive LDL-C values < 15 mg/dL and propensity score-matched patients on placebo

	All ( N  = 3128)	Alirocumab ( N  = 782)	Placebo ( N  = 2346)
LDL-C, mmol/L	2.0 ± 0.5	2.0 ± 0.6	2.0 ± 0.5
Non-HDL-C, mmol/L	2.8 ± 0.7	2.8 ± 0.7	2.8 ± 0.6
Total cholesterol, mmol/L	3.9 ± 0.7	3.9 ± 0.8	3.9 ± 0.7
HDL-C, mmol/L	1.1 ± 0.3	1.1 ± 0.3	1.1 ± 0.3
Fasting triglycerides, mmol/L	1.8 ± 1.1	1.8 ± 0.9	1.8 ± 1.1
Lipoprotein(a), mg/dL	18.8 ± 23.1	19.3 ± 22.4	18.7 ± 23.3
Apolipoprotein B, mg/dL	75.4 ± 16.0	76.0 ± 17.5	75.2 ± 15.4
Apolipoprotein A1, mg/dL	129.9 ± 22.9	129.2 ± 22.3	130.1 ± 23.1
Apolipoprotein B/Apolipoprotein A1 ratioa	0.6 ± 0.2	0.6 ± 0.2	0.6 ± 0.2
Total cholesterol/HDL-C ratioa	3.7 ± 1.0	3.7 ± 0.9	3.7 ± 1.0

Data are presented as mean ± SD

HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Q quartile, SD standard deviation.

^a Ratios were only calculated if the 2 samples were collected at the same visit.

The original article has been updated and the correct values are also given below in bold.

The second paragraph in page 4 should read:

A total of 4305 patients in the alirocumab group had ≥ 2 consecutive LDL-C values < 25 mg/dL (0.65 mmol/L) and were matched to 4305 patients from the placebo group with similar baseline characteristics (Tables 2 and 3). Baseline characteristics of these patients included mean age 59 years, male sex (81%), diabetes (33%); and mean body mass index 28.3 kg/m2, LDL-C 2.1 mmol/L, lipoprotein (a) 28.6 mg/dL, and apolipoprotein A1 131.6 mg/dL. A total of 782 patients in the alirocumab group had ≥ 2 consecutive LDL-C values < 15 mg/dL (0.39 mmol/L) and were matched to 2346 patients from the placebo group with similar baseline characteristics (Tables 4 and 5). Baseline characteristics of these patients included mean age 59 years, male sex (81%), diabetes (33%); and mean body mass index 27.3 kg/m2, LDL-C 2.0 mmol/L, lipoprotein (a) 18.8 mg/dL, and apolipoprotein A1 129.9 mg/dL.